BioPoint Inc

New clinical data from Compass and Definium is boosting confidence in psychedelic therapies for mental health. The results strengthen momentum for the emerging treatment field. https://www.biospace.com/drug-development/psychedelics-surge-again-as-compass-definium-provide-more-clinical-validation

Psychedelics surge again as Compass, Definium provide more clinical validation Psychedelics are gaining momentum in depression, with one treating physician predicting that the drug class could “wipe out the SSRIs” if safety and durability hold up.

Veradermics' stock has surged 656% since its IPO, fueled in part by growing interest in hair loss treatments linked to obesity drugs. The company is benefiting from rising demand driven by the GLP-1 market. https://www.biospace.com/business/hair-loss-biotech-veradermics-up-656-since-its-ipo-credits-the-obesity-boom

Hair loss biotech Veradermics, up 656% since its IPO, credits the obesity boom After debuting on the public markets with $256.3 million and raking in an additional $472 million, Veradermics has emerged as one of biotech’s biggest post-IPO standouts. CEO Reid Waldman credits the weight loss craze for establishing consumer-driven channels.